HCV Services and COVID-19 Provider Survey

Question Title

* 1. What type of healthcare provider are you? (Select all that apply.)

RN/LPN

PharmD

PsyD

Social Worker (MSW, LCSW, DSW)

Other (please specify)

Question Title

* 2. What type of setting do you practice in?

Private Practice

Health Center/FQHC/FQHC Look-a-Like

Ryan White HIV/AIDS Program

State Health Department

Local (city/county) Health Department

Academic Health Center

Community Based Organization

Infectious Disease Clinic

HIV Clinic

Hospital

Other (please specify)

Question Title

* 3. Where is your practice setting located?

City/Town

State/Province

ZIP/Postal Code

Country

Question Title

* 4. How has COVID-19 impacted your delivery of hepatitis C (HCV) services?

	Significantly decreased	Somewhat decreased	No change	Somewhat increased	Significantly increased	N/A
HCV prevention (e.g. harm reduction, syringe services)	HCV prevention (e.g. harm reduction, syringe services) Significantly decreased	HCV prevention (e.g. harm reduction, syringe services) Somewhat decreased	HCV prevention (e.g. harm reduction, syringe services) No change	HCV prevention (e.g. harm reduction, syringe services) Somewhat increased	HCV prevention (e.g. harm reduction, syringe services) Significantly increased	HCV prevention (e.g. harm reduction, syringe services) N/A
HCV screening	HCV screening Significantly decreased	HCV screening Somewhat decreased	HCV screening No change	HCV screening Somewhat increased	HCV screening Significantly increased	HCV screening N/A
HCV treatment	HCV treatment Significantly decreased	HCV treatment Somewhat decreased	HCV treatment No change	HCV treatment Somewhat increased	HCV treatment Significantly increased	HCV treatment N/A

Question Title

* 5. Since the onset of COVID-19, how have you delivered the following HCV services?

	Through telemedicine	In person	Both through telemedicine and in person	Not conducting these services due to pandemic	Not conducting these services due to other reason (e.g. recent change in funding)
HCV prevention (e.g. harm reduction, syringe services)	HCV prevention (e.g. harm reduction, syringe services) Through telemedicine	HCV prevention (e.g. harm reduction, syringe services) In person	HCV prevention (e.g. harm reduction, syringe services) Both through telemedicine and in person	HCV prevention (e.g. harm reduction, syringe services) Not conducting these services due to pandemic	HCV prevention (e.g. harm reduction, syringe services) Not conducting these services due to other reason (e.g. recent change in funding)
HCV screening	HCV screening Through telemedicine	HCV screening In person	HCV screening Both through telemedicine and in person	HCV screening Not conducting these services due to pandemic	HCV screening Not conducting these services due to other reason (e.g. recent change in funding)
HCV treatment	HCV treatment Through telemedicine	HCV treatment In person	HCV treatment Both through telemedicine and in person	HCV treatment Not conducting these services due to pandemic	HCV treatment Not conducting these services due to other reason (e.g. recent change in funding)

Question Title

* 6. How has COVID-19 interrupted HCV prevention services? (Select all that apply.)

Unable to meet clients in the field (e.g. clients must come to office)

Unable to provide sterile syringe services

Clients choosing to discontinue engagement in harm reduction services

Unable to provide Medically-Assisted Treatment (MAT)

Unable to convene meetings/therapy sessions for people with SUD

Other (please specify)

Question Title

* 7. How has COVID-19 interrupted HCV screening and linkage to care services? (Select all that apply.)

Patients choosing to opt out of HCV screening

Unable to conduct HCV screening in the field/in outreach settings

Unable to conduct HCV screening entirely

Unable to link clients to HCV treatment provider

Unable to pay for medication or services related to HCV screening and linkage to care

Unable to conduct confirmatory (RNA) testing

Other (please specify)

Question Title

* 8. Has COVID-19 caused interruptions in HCV treatment among existing clients with HCV?

Yes

I Don't Know

N/A - My practice does not provide HCV treatment.

Question Title

* 9. Are you currently taking on new HCV patients during COVID-19 practice disruptions?

Yes

I Don't Know

N/A - My practice does not provide HCV treatment.

Question Title

* 10. How has COVID-19 interrupted HCV treatment services? (Select all that apply.)

Patients choosing to not start HCV treatment

Unable to complete labs

Unable to complete treatment check-ins

Unable to access prescription from pharmacy

Unable to fill prescription remotely

Unable to pay for medication or services related to HCV treatment

Unable to adhere to HCV treatment due to circumstance changes (e.g. housing/living situation)

Patients choosing to discontinue HCV treatment

COVID-19 has not interrupted HCV treatment services

Other (please specify)

Question Title

* 11. How has your practice setting adapted delivery of services to continue to provide accessible HCV screening and treatment services? (Select all that apply.)

Limiting number of visits prior to and/or during HCV treatment

Conducting HCV patient visits via telehealth ONLY

Shipping HCV treatment/medication to patient's home

Conducting bloodwork outside of hospital/clinic setting (e.g. patient's car)

No adaptations have been made

Providing rapid HCV test kits to clients

Other (please specify)

HCV Services and COVID-19 Provider Survey

Question Title

* 1. What type of healthcare provider are you? (Select all that apply.)

Question Title

* 2. What type of setting do you practice in?

Question Title

* 3. Where is your practice setting located?

Question Title

* 4. How has COVID-19 impacted your delivery of hepatitis C (HCV) services?

Question Title

* 5. Since the onset of COVID-19, how have you delivered the following HCV services?

Question Title

* 6. How has COVID-19 interrupted HCV prevention services? (Select all that apply.)

Question Title

* 7. How has COVID-19 interrupted HCV screening and linkage to care services? (Select all that apply.)

Question Title

* 8. Has COVID-19 caused interruptions in HCV treatment among existing clients with HCV?

Question Title

* 9. Are you currently taking on new HCV patients during COVID-19 practice disruptions?

Question Title

* 10. How has COVID-19 interrupted HCV treatment services? (Select all that apply.)

Question Title

* 11. How has your practice setting adapted delivery of services to continue to provide accessible HCV screening and treatment services? (Select all that apply.)

Question Title

* 12. What is your biggest concern for how COVID-19 will impact health outcomes of your patients living with or at risk for HCV?